Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0424
Source ID: NCT02957877
Associated Drug: Nadroparin
Title: LMWH Infusion as Anticoagulation for Home HD
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Endstage Renal Disease
Interventions: DRUG: Nadroparin|DRUG: Unfractionated heparin
Outcome Measures: Primary: Prothrombin time, Prothrombin time is monitored in both of the LMWH and UFH arms, Pre-dialysis; the 2nd, 4th, 6th and 8th hours of dialysis|Activated partial thromboplastin time, Activated partial thromboplastin time is monitored in both of the LMWH and UFH arms, Pre-dialysis; the 2nd, 4th, 6th and 8th hours of dialysis|Anti-Xa level, Anti-Xa level is only monitored in the LMWH arm, Pre-dialysis; the 2nd, 4th, 6th and 8th hours of dialysis; 24 hours after administration of LMWH|Dialyser urea and creatinine clearances, Dialyser urea and creatinine clearances are evaluated in both of the LMWH and UFH arms, At 15 mins after starting hemodialysis and 15 mins before the end of hemodialysis|Dialyser thrombus score, Dialyser thrombus score is evaluated in both of the LMWH and UFH arms, At the end of hemodialysis (8th hour) |
Sponsor/Collaborators: Sponsor: Alice Ho Miu Ling Nethersole Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 12
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2016-03
Completion Date: 2018-05
Results First Posted:
Last Update Posted: 2016-11-08
Locations: Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong
URL: https://clinicaltrials.gov/show/NCT02957877